Targets › CD138
3 programs from 3 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on CD138, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital of Soochow University | CART-138/BCMA/19/more Multi-antigen CAR-T cell therapy targeting CD138, BCMA (TNFRSF17), CD19, and additional an | CD138, TNFRSF17, CD19 | Phase 1 | Multiple Myeloma | Dec 2026 |
| Nammi Therapeutics | QXL138AM Anti-CD138 IgG1 antibody fused to human interferon alpha 2a | CD138 | Phase 1 | Ovarian Cancer | Dec 2027 |
| UNC Lineberger Comprehensive Cancer Center | ATLCAR.CD138 anti-CD138 CAR-T cell therapy | CD138 | Phase 1 | Multiple Myeloma | Aug 2039 |
Multiple Myeloma (2) Ovarian Cancer (1)
other (2), protein or peptide (1)
UNC Lineberger Comprehensive Cancer Center (1) Nammi Therapeutics (1) The First Affiliated Hospital of Soochow University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.